M. Pharm.

Mr. Naveen Kumar Panicker joined as Lecturer in Amrita School of Pharmacy in October 2011. Currently working as Assistant Professor in the Department of Pharmacy Practice. Completed B.Pharm and M.Pharm from Annamalai University. Experience include 5 years in pharma marketing and 10 yrs as branch-in-charge of a branch of chain pharmacy in Sultanate of Oman. Publications include both in national and international indexed journals. Guide for research projects of M. Pharm and Pharm. D. students. Areas of interest include promoting rational use of drugs and community based projects. Also, actively involved in the co-curricular and extra curricular activities of the school.


Publication Type: Journal Article

Year of Publication Publication Type Title


Journal Article

Jab Parvathy, Philip, T. Mab, Abhijith, Kab, Sreeni, Sab, N.K.a Panicker, and Nambiar, Vc, “Fluoxetine vs Venlafaxine: Economic evaluation in post stroke depression”, International Journal of Pharmaceutical Sciences Review and Research, vol. 41, pp. 234-236, 2016.[Abstract]

The primary aim of this study is to compare the antidepressants Venlafaxine and Fluoxetine in terms of their Cost-effectiveness. A prospective, comparative follow-up study was conducted in stroke unit. Sixty randomly selected stroke patients diagnosed with PSD and who met the inclusion criteria were classified into two subgroups with 30 patients each treated with antidepressants fluoxetine and venlafaxine. The HDRS17 was used to assess the effectiveness of the drugs by taking a baseline value at the time of initiation of therapy and followed up regularly at time intervals of 2, 4 and 8 weeks. The economic profiles of both drugs were determined by using cost-effectiveness analysis (ICER and ACER). The efficacy of the drugs was determined using the HDRS17, which showed an improvement in the score from baseline to 8 weeks. While performing cost-effectiveness analysis by comparing the cost and effect of fluoxetine against venlafaxine, incremental cost was positive (19.98) and the incremental effect was negative (-6). While performing the ACER for each drug the value obtained for fluoxetine was 6.02 and 4.96 for venlafaxine. The results of ICER and ACER show that venlafaxine is the cost-effective drug. Economic analysis shows that venlafaxine is the cost-effective drug among venlafaxine and fluoxetine.

More »»


Journal Article

Aa Neetha, N.K.a Panicker, and Sidharthan, Nb, “Immediate adverse drug events with rituximab therapy in non-malignant hematological disorders”, Asian Journal of Pharmaceutical and Clinical Research, vol. 8, pp. 71-72, 2015.[Abstract]

Rituximab therapy has become a promising therapeutic option for various non-malignant hematological disorders, after being reported by many case reports. The objective of this study was to evaluate the immediate, infusion-related adverse drug events (ADE) of patients who received rituximab for non-malignant, hematological disorders, in a tertiary healthcare center in India. 14 patients (6 with primary immune thrombocytopenia, 4 with autoimmune hemolytic anemia, 3 with thrombotic thrombocytopenic purpura, 1 with acquired hemophilia) were enrolled in the study. Patients were assessable for immediate infusion-related toxicity noted predominately within 5 hrs of administration of rituximab infusion. Rituximab therapy was tolerated without major ADE. None of the patients experienced high-grade adverse events. The population who experienced ADE (Grades 1-2) frequently had toxicities that suspected to result from infusion-related cytokine release syndrome (IRCRS) and sometimes required cessation of the infusion and supportive intervention. Patients were monitored for 20 types of ADEs associated with IRCRS. 11 types of; mild to moderate (Grades 1 and 2) toxicities resulting from IRCRS were experienced by patients. Mean patients who experienced IRCRS was 1.95 (13.93%), whereas majority of the study population tolerated therapy without IRCRS (86.78%). Among other toxicities, Grade 2 urinary tract infection (UTI) (n=2, 14.29%); Grade 2 hyperglycemia (n=1, 7.14%) and Grade 1 myalgia (n=1, 7.14%) were observed. Toxicity profile of patients with non-malignant hematological disorders shows that rituximab is a safer biological therapy. © 2015, Asian Journal of Pharmaceutical and Clinical Research. All Rights Reserved.

More »»
Faculty Research Interest: 
NIRF 2018
  • Amrita on Social Media

  • Contact us

    Amrita Vishwa Vidyapeetham
    Amritanagar, Coimbatore - 641 112
    Tamilnadu, India
    • Fax: +91-422-2686274
    • Coimbatore : +91 (422) 2685000
    • Amritapuri   : +91 (476) 280 1280
    • Bengaluru    : +91 (080) 251 83700
    • Kochi              : +91 (484) 280 1234
    • Mysuru          : +91 (821) 234 3479
    • Contact Details »